-

Bayer Introduces Midol® in Motion, Empowering Menstruators to Find PMS Relief Through Movement

WHIPPANY, N.J.--(BUSINESS WIRE)--Up to 90% of menstruators experience PMS symptoms1, many of which can meaningfully impact day‑to‑day life. Bayer today announced the launch of Midol® in Motion, a campaign focused on helping people better understand and relieve 7 common PMS symptoms – period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention – through a combination of symptom relief and supportive movement.

Midol® in Motion is grounded on consumer experience and research:

  • Period symptoms can interrupt movement and daily routines, making it harder to stay active. Research shows that 55% and 61% of women change their training schedules due to menstrual and premenstrual symptoms, respectively, and nearly two in five women skip workouts altogether during their period.2,3
  • Exercise is a powerful tool for easing PMS pain, fatigue, and other disruptive symptoms.
  • When paired with Midol® Complete’s multi‑symptom* relief, Midol® in Motion highlights how people can stay active and maintain their routines. *Relief of period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention.

As part of the campaign, Midol® will be hosting an immersive afternoon of movement and education designed to help people better understand and relieve PMS symptoms. The experience will include live workouts led by Midol® partner and Barre Certified fitness influencer and instructor, Jenna Palek, as well as Midol® partner and NASM and Barre certified fitness influencer and instructor, Makena Rae Diehl, focusing on ways of movement to target and help alleviate different period symptoms. The afternoon will also include interactive stations highlighting different solutions to help relieve common PMS symptoms, so they don’t get in the way of daily routines.

Beyond the live event, the Midol® in Motion campaign extends across a broader digital and social ecosystem, bringing the movement to life through ongoing content across Midol®'s owned and partner channels. This includes a series of original social content highlighting expert guidance, intentional movement routines, and practical ways to help manage common PMS symptoms as a part of everyday life. Through creator partnerships and educational storytelling, the campaign aims to show how people can stay on track with their routines during their period.

Midol® in Motion focuses on helping people reclaim their physical comfort and daily routines during their period,” said Lisa Perez, Bayer General Manager of PCD and Nutritionals. “By pairing symptom relief from Midol® Complete with supportive movement, we’re helping menstruators address multiple PMS symptoms that can get in the way of everyday activities. Period symptoms can make people feel unlike themselves. Our goal is to help them address those period symptoms so they can stay connected to the movement and routines that help them feel like themselves again.”

Midol® in Motion will highlight intentional movement modalities shown to help support the body during the menstrual cycle, including:

  • Aerobic + cardio: Light cardio such as walking, jogging, or biking to help ease bloating and water retention
  • Yoga + Pilates: Core focused exercises and continuous movement designed to help relieve cramps, backache, and muscle aches
  • Meditation + Stretching: Slow, intentional movements help menstruators with headaches and fatigue.

“Periods can make movement feel harder than it should, and I know firsthand how easy it is to cancel workouts when fatigue or bloating hits,” explains Midol® partner and fitness influencer Jenna Palek. “Midol® in Motion is about choosing intentional movement that supports how you physically feel. When I pair comfort‑first movement with Midol® Complete (as directed), I’m able to relieve multiple PMS symptoms* to get back to feeling like myself.”

*period cramps, bloating, fatigue, backaches, muscle aches, headaches, and water retention

Follow the movement via the Midol® social channels, @Midol on Instagram and TikTok.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2025, the Group employed around 88,000 people and had sales of 45.6 billion euros. R&D expenses amounted to 5.8 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

References:

1. Li H, Sarokhani M, Gilan MHS, Valizade R, Sayehmiri K. Prediction premenstrual syndrome (PMS) with anxiety, and depression in female students. BMC Psychiatry. 2025 Aug 18;25(1):794. doi: 10.1186/s12888-025-07250-z. PMID: 40826390; PMCID: PMC12359940.

2. Prado RCR, Willett HN, Takito MY, Hackney AC. Impact of Premenstrual Syndrome Symptoms on Sport Routines in Nonelite Athlete Participants of Summer Olympic Sports. Int J Sports Physiol Perform. 2022 Dec 28;18(2):142-147. doi: 10.1123/ijspp.2022-0218. PMID: 36577421.

3. Mahina. Beyond Blood: The Unseen Burden of Every Cycle. Mahina; 2025 May 28. Available from: https://mahina.co/pages/beyond-blood-report

Contacts

For U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

Bayer

GER:BAYN

Release Versions

Contacts

For U.S. media inquiries:
Christin Miller
Director of Integrated Strategic Communications
Email: christin.miller@bayer.com

More News From Bayer

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio...

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key Facts The sNDA was supported by the Phase III FINE-ONE trial, which showed KERENDIA significantly reduced urine albumin-to-creatinine rati...

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT’S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OC...
Back to Newsroom